Elicio Therapeutics (ELTX) Restructuring Costs (2022)
Elicio Therapeutics (ELTX) reported Restructuring Costs of $3.1 million for Q4 2022, up 12.48% quarter-over-quarter from $2.8 million in Q3 2022.
Elicio Therapeutics (ELTX) Restructuring Costs (2022) Analysis & Trends
Elicio Therapeutics has reported Restructuring Costs for 1 years, with the latest figure at $3.1 million in Q4 2022.
- For the quarter ending Q4 2022, Restructuring Costs changed N/A year-over-year to $3.1 million; the trailing twelve-month figure through Dec 2022 stood at $5.9 million (changed N/A YoY), and the FY2022 full-year result was $9.2 million, changed N/A from the prior year.
- Restructuring Costs for Q4 2022 stood at $3.1 million, up from $2.8 million in the prior quarter.
- The five-year high for Restructuring Costs was $3.1 million in Q4 2022, with the low at $2.8 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Elicio Therapeutics | 270.44 Mn | 255.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 3.15 Mn |
| Sep 30, 2022 | 2.80 Mn |